BioWorld

Sep. 22, 2004

Xenon, Novartis Enter $157M Deal For Obesity Compounds

In a deal that could bring Xenon Pharmaceuticals Inc. $157 million in pre-commercial payments, Novartis Pharma AG agreed to research, develop and commercialize compounds from Xenon's SCD1 drug development program. (BioWorld Today) Read More

'Two Pathways' Now Mapped For Anidulafungin's Approval

Multitasking Histone Molecule SAHA Affects Kidney Disease

Coley's Anti-Terrorism TLRs Get Another $16.9M Contract

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 23, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

Nankai University and Accendatech present new majusculamide D derivatives

BioWorld Science

Scientists from Nankai University Tianjin and Accendatech Technology Co. Ltd. have identified a majusculamide D derivative found to be useful for the treatment of...